Abstract
Recently, Feng et al published a significant study. Through multi-omics analysis, their research team revealed associations between fecal metabolome, gut bacteria, and serum indicators in patients with hepatocellular carcinoma (HCC). These results suggest that the composition of the metabolome and gut bacteria in fecal samples hold promise as potential biomarkers for the diagnosis of HCC. After carefully reviewing their work, we offer two points of insight: (1) The influence of different factors on gut microbiota changes in HCC; and (2) The impact of the hepatitis B virus and antiviral drugs on the gut microbiota of patients with HCC.